NOVASEP and LYSOGENE Announce Their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product

LYON, France and PARIS, May 26, 2020 /PRNewswire/ -- Novasep, a leading supplier of services and technologies for the life sciences industry, and Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the...

from
https://www.prnewswire.com:443/news-releases/novasep-and-lysogene-announce-their-new-collaboration-for-development-and-production-of-gm1-gangliosidosis-gene-therapy-product-301064726.html